Cerdelga (eliglustat) — Point32Health
long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers, intermediate metabolizers, or poor metabolizers as detected by an FDA-cleared test
Initial criteria
- Documented diagnosis of Type 1 Gaucher disease
- Documentation diagnosis is confirmed by at least one (1) of the following: (a) An enzyme assay test showing reduced activity of the enzyme glucocerebrosidase OR (b) Genetic testing
- Patient age ≥ 18 years
- Documentation the patient is symptomatic (e.g., thrombocytopenia, anemia, hepatomegaly, splenomegaly, bone disease)
- Documentation the patient is a CYP2D6 extensive metabolizer, intermediate metabolizer, or poor metabolizer as detected by a Food and Drug Administration cleared test